Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation

How I assess comorbidities before hematopoietic cell transplantation

(2013) M. L. Sorror   BLOOD

Back to the Future: Mismatched Unrelated Donor, Haploidentical Related Donor, or Unrelated Umbilical Cord Blood Transplantation?

(2012) Claudio Anasetti et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study

(2012) R. Raimondi et al.   BLOOD

A perspective on the selection of unrelated donors and cord blood units for transplantation

(2012) S. R. Spellman et al.   BLOOD

A disease risk index for patients undergoing allogeneic stem cell transplantation

(2012) P. Armand et al.   BLOOD

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

(2012) H. J. Deeg et al.   BLOOD

HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1

(2012) Jeffrey M. Venstrom et al.   NEW ENGLAND JOURNAL OF MEDICINE

MHC-Resident Variation Affects Risks After Unrelated Donor Hematopoietic Cell Transplantation

(2012) E. W. Petersdorf et al.   Science Translational Medicine

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

(2011) Mohamed L. Sorror et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

(2010) Eneida R. Nemecek et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase

(2010) J. Pavlu et al.   BLOOD

Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

(2010) Brian L. McClune et al.   JOURNAL OF CLINICAL ONCOLOGY

Health Care Reform and Cost Control

(2010) Peter R. Orszag et al.   NEW ENGLAND JOURNAL OF MEDICINE

Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

(2009) Benjamin D. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

(2009) ZiYi Lim et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor

(2008) Navneet S. Majhail et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

(2008) Mohamed L. Sorror et al.   JOURNAL OF CLINICAL ONCOLOGY